These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 10911466

  • 1. [Methotrexate treatment in refractory juvenile rheumatoid arthritis].
    Brik R.
    Harefuah; 1998 Dec 01; 135(11):509-11, 567. PubMed ID: 10911466
    [Abstract] [Full Text] [Related]

  • 2. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb 01; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 3. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis.
    Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A.
    J Rheumatol; 1995 Aug 01; 22(8):1574-6. PubMed ID: 7473486
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
    Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A, Pediatric Rheumatology International Trials Organization.
    Arthritis Rheum; 2004 Jul 01; 50(7):2191-201. PubMed ID: 15248217
    [Abstract] [Full Text] [Related]

  • 5. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.
    Rheumatology (Oxford); 2004 May 01; 43(5):619-25. PubMed ID: 14983105
    [Abstract] [Full Text] [Related]

  • 6. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.
    Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A.
    Ann Rheum Dis; 2008 Mar 01; 67(3):370-4. PubMed ID: 17660217
    [Abstract] [Full Text] [Related]

  • 7. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May 01; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 8. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep 01; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 9. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.
    Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MA, Hollingworth P, Cawkwell G, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organisation (PRINTO).
    Ann Rheum Dis; 2010 Aug 01; 69(8):1479-83. PubMed ID: 20525842
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F.
    Arthritis Rheum; 2005 Feb 01; 52(2):548-53. PubMed ID: 15693004
    [Abstract] [Full Text] [Related]

  • 11. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.
    Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, Bernstein BH.
    J Rheumatol; 1997 Dec 01; 24(12):2436-43. PubMed ID: 9415655
    [Abstract] [Full Text] [Related]

  • 12. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.
    Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhães C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organization (PRINTO).
    Ann Rheum Dis; 2008 Mar 01; 67(3):309-14. PubMed ID: 17875547
    [Abstract] [Full Text] [Related]

  • 13. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M, Schettler JD, Fries JF.
    J Rheumatol; 2000 May 01; 27(5):1139-47. PubMed ID: 10813279
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2006 Jun 01; 54(6):1987-94. PubMed ID: 16732547
    [Abstract] [Full Text] [Related]

  • 15. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
    Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ.
    Arthritis Rheum; 2009 Jan 15; 61(1):46-51. PubMed ID: 19116975
    [Abstract] [Full Text] [Related]

  • 16. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN.
    J Rheumatol; 2004 Jan 15; 31(1):179-82. PubMed ID: 14705239
    [Abstract] [Full Text] [Related]

  • 17. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis.
    Foeldvari I, Wierk A.
    J Rheumatol; 2005 Feb 15; 32(2):362-5. PubMed ID: 15693100
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate in the treatment of children with chronic arthritis--long-term observations of efficacy and safety.
    Huang JL.
    Br J Clin Pract; 1996 Sep 15; 50(6):311-4. PubMed ID: 8983319
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
    Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM, iRAMT Study Group.
    Curr Med Res Opin; 2005 Aug 15; 21(8):1181-90. PubMed ID: 16083527
    [Abstract] [Full Text] [Related]

  • 20. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb 15; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.